# RVPH catalysts: REVIVA PHARMACEUTICALS HOLDINGS, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/rvph/catalysts

> REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) has 1 upcoming catalyst. The next is the brilaroxazine trial start, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for RVPH?

REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) has 1 upcoming catalyst. The next is the brilaroxazine trial start, 1H 2027. SEC Form 10-Q: "We plan to initiate patient enrollment in the RECOVER-2 Phase 3 study for brilaroxazine in schizophrenia (the "RECOVER-2 Trial") in the first half of 2027, subject to additional financing." [Calendar and source filings](https://sec-api.dev/companies/rvph/catalysts)

Source: SEC Form 10-Q, accession 0001437749-26-036648, https://www.sec.gov/Archives/edgar/data/1742927/000143774926036648/rvph20260930_10q.htm (retrieved 2026-11-14). Last confirmed 2026-11-13. Cite: https://sec-api.dev/companies/rvph/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | REVIVA PHARMACEUTICALS HOLDINGS, INC. |
| Ticker | RVPH (OTC) |
| SEC CIK | 1742927 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/rvph |

## Cash runway

Cash $17.5M as of 2026-09-30; quarterly burn $2.2M; about 24.0 months of runway at that rate (XBRL company facts, accession 0001437749-26-036648).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| October 30, 2023 | [Brilaroxazine topline data readout](https://sec-api.dev/pdufa/brilaroxazine) | RVPH | schizophrenia | completed, positive | "On October 30, 2023, we announced positive topline results and successful completion of our pivotal RECOVER-1 Trial evaluating the efficacy, safety and tolerability of once-daily brilaroxazine, a serotonin dopamine signaling modulator in adults with schizophrenia." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1742927/000143774925034827/rvph20250930_10q.htm)) |
| October 30, 2023 | [REVIVA PHARMACEUTICALS HOLDINGS, INC. topline data readout](https://sec-api.dev/companies/rvph/catalysts) | RVPH |  | completed, positive | "On October 30, 2023, we announced positive topline results of the RECOVER Trial." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1742927/000143774925029530/rvph20250919_424b5.htm)) |
| November 14, 2024 | [REVIVA PHARMACEUTICALS HOLDINGS, INC. earnings report](https://sec-api.dev/companies/rvph/catalysts) | RVPH |  | completed | "Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1742927/000143774924035391/ex_748171.htm)) |
| Dec 2024 | [Brilaroxazine topline data readout](https://sec-api.dev/pdufa/brilaroxazine) | RVPH |  | scheduled | "We expect to report topline data from our OLE Trial in December 2024, with the OLE Trial expected to complete in Q-1 2025, and we expect to initiate the registrational RECOVER-2 Trial in the first quarter of 2025, subject to receipt of additional financing, with completion anticipated in the first quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1742927/000143774924035375/rvph20240930_10q.htm)) |
| December 16, 2024 | [Brilaroxazine interim data readout](https://sec-api.dev/pdufa/brilaroxazine) | RVPH | schizophrenia | completed, positive | "On December 16, 2024, we announced positive preliminary topline data from, and on June 2, 2025, we announced a positive full dataset and successful completion of, our Phase 3 RECOVER open label extension (the "OLE" or the "OLE Trial") a 1-year study evaluating the long-term safety, tolerability and efficacy of brilaroxazine in patients with schizophrenia." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1742927/000143774925034827/rvph20250930_10q.htm)) |
| March 31, 2025 | [REVIVA PHARMACEUTICALS HOLDINGS, INC. earnings report](https://sec-api.dev/companies/rvph/catalysts) | RVPH |  | completed | "Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1742927/000143774925010191/ex_796258.htm)) |
| May 15, 2025 | [REVIVA PHARMACEUTICALS HOLDINGS, INC. earnings report](https://sec-api.dev/companies/rvph/catalysts) | RVPH |  | completed | "Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1742927/000143774925017185/ex_818734.htm)) |
| August 14, 2025 | [REVIVA PHARMACEUTICALS HOLDINGS, INC. earnings report](https://sec-api.dev/companies/rvph/catalysts) | RVPH |  | completed | "Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1742927/000143774925026971/ex_853315.htm)) |
| November 13, 2025 | [REVIVA PHARMACEUTICALS HOLDINGS, INC. earnings report](https://sec-api.dev/companies/rvph/catalysts) | RVPH |  | completed | "Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1742927/000143774925034846/ex_886716.htm)) |
| March 30, 2026 | [REVIVA PHARMACEUTICALS HOLDINGS, INC. earnings report](https://sec-api.dev/companies/rvph/catalysts) | RVPH |  | completed | "Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1742927/000143774926010140/ex_937921.htm)) |
| Q2 2026 | [Brilaroxazine trial start](https://sec-api.dev/pdufa/brilaroxazine) | RVPH |  | scheduled | "Subject to sufficient financing, Reviva may also initiate a Phase 3 trial of brilaroxazine for negative symptoms or bipolar disorder (the "Negative Symptoms/Bipolar Trial") in the second quarter of 2026, and based on this timeline of intended trial initiation, the Company plans for the Negative Symptoms/Bipolar Trial data to be available in the third quarter of 2027, with a potential supplemental New Drug Application (sNDA) targeted for filing in the fourth quarter of 2027 for potential approval in the fourth quarter of 2028." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1742927/000143774925038602/rvph20251216_8k.htm)) |
| May 13, 2026 | [REVIVA PHARMACEUTICALS HOLDINGS, INC. earnings report](https://sec-api.dev/companies/rvph/catalysts) | RVPH |  | completed | "Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1742927/000143774926016760/ex_962420.htm)) |
| Q3 2026 | [Brilaroxazine topline data readout](https://sec-api.dev/pdufa/brilaroxazine) | RVPH |  | scheduled | "We expect to initiate the registrational RECOVER-2 Trial in mid-2025, subject to receipt of additional financing, with topline readout anticipated in the third quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1742927/000143774925017191/rvph20250331_10q.htm)) |
| August 12, 2026 | [REVIVA PHARMACEUTICALS HOLDINGS, INC. earnings report](https://sec-api.dev/companies/rvph/catalysts) | RVPH |  | completed | "Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1742927/000143774926027356/ex_1003442.htm)) |
| Q4 2026 | [Brilaroxazine NDA/BLA submission](https://sec-api.dev/pdufa/brilaroxazine) | RVPH |  | scheduled | "These data from our brilaroxazine clinical development plan will potentially support the planned NDA submission to the FDA in the fourth quarter of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1742927/000143774925010791/rvph20241231_10k.htm)) |
| November 12, 2026 | [REVIVA PHARMACEUTICALS HOLDINGS, INC. earnings report](https://sec-api.dev/companies/rvph/catalysts) | RVPH |  | completed | "Reviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1742927/000143774926036647/ex_1042036.htm)) |
| 1H 2027 | [Brilaroxazine trial start](https://sec-api.dev/pdufa/brilaroxazine) | RVPH |  | scheduled | "We plan to initiate patient enrollment in the RECOVER-2 Phase 3 study for brilaroxazine in schizophrenia (the "RECOVER-2 Trial") in the first half of 2027, subject to additional financing." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1742927/000143774926036648/rvph20260930_10q.htm)) |

## Drugs

- [Brilaroxazine](https://sec-api.dev/pdufa/brilaroxazine): schizophrenia

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/rvph/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "RVPH catalysts: REVIVA PHARMACEUTICALS HOLDINGS, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/rvph/catalysts

```bibtex
@misc{secapidev_companies_rvph_catalysts_20261116,
  title        = {RVPH catalysts: REVIVA PHARMACEUTICALS HOLDINGS, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/rvph/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_rvph_catalysts_20261116","title":"RVPH catalysts: REVIVA PHARMACEUTICALS HOLDINGS, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/rvph/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
